The Therapeutic Monoclonal Antibody Bamlanivimab Does Not Enhance SARS-CoV-2 Infection by FcR-Mediated Mechanisms

Cross, RW; Wiethoff, CM; Brown-Augsburger, P; Berens, S; Blackbourne, J; Liu, L; Wu, XH; Tetreault, J; Dodd, C; Sina, R; Witcher, DR; Newcomb, D; Frost, D; Wilcox, A; Borisevich, V; Agans, KN; Woolsey, C; Prasad, AN; Deer, DJ; Geisbert, JB; Dobias, NS; Fenton, KA; Strifler, B; Ebert, P; Higgs, R; Beall, A; Chanda, S; Riva, L; Yin, X; Geisbert, TW

Geisbert, TW (通讯作者)，Univ Texas Med Branch, Dept Microbiol & Immunol, Galveston, TX 77555 USA.;Geisbert, TW (通讯作者)，Univ Texas Med Branch, Galveston Natl Lab, Galveston, TX 77555 USA.;Wiethoff, CM (通讯作者)，Eli Lilly & Co, Indianapolis, IN 46285 USA.

PATHOGENS, 2023; 12 (12):

Abstract

As part of the non-clinical safety package characterizing bamlanivimab (SARS-CoV-2 neutralizing monoclonal antibody), the risk profile for antibody-de......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索